This current study discovered that DG treatment first increased the levels of taurine-conjugated BAs by suppressing the abundance of BSH related microbes in intestine of mice with obesity, which further resulted in restraint of ileal FXR-FGF15 axis to bring several obesity-related metabolic improvements like lower serum glucose and insulin levels, increased insulin sensitivity, few hepatic steatosis and resistance to weight gain. This evidence concerns the gene INS and fatty liver disease.